Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | STAT3 | P40763 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31326913 | 0.95 | CRBN (0.65) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL28576091 | 0.94 | CRBN (0.64) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL19747588 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326918 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL22291385 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31361483 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326912 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31326916 | 0.93 | CRBN (0.63) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL23705748 | 0.92 | CRBN (0.60) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Trifluoroacetic Acid SCHEMBL31361548 | 0.92 | CRBN (0.62) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| CN-118930546-A | PROTAC compound for targeted degradation of DAPK1 protein as well as preparation method and application thereof | 福建医科大学 | 2024-11-12 | — | — | CN | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | UNIV MICHIGAN REGENTS (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-01-12 | — | — | US | disclosed |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3331905-B1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA FARBER CANCER INST INC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3331905-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | Dana-Farber Cancer Institute, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331906-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3256470-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | Dana Farber Cancer Institute, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017024317-A2 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885HDAC1 2291/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | CRBN 158/4885DDB1 10/4885HDAC1 4320/4885 |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | EZH2, BMI1, SUZ12 | CRBN 53/4885DDB1 440/4885HDAC1 90/4885 |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | CRBN 53/4885DDB1 440/4885HDAC1 90/4885 |
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | PTPN1, PTPRS, PPM1D | CRBN 77/4885DDB1 723/4885HDAC1 1031/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885HDAC1 2077/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885HDAC1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.